Detalhe da pesquisa
1.
A multicentre randomised controlled trial to compare the pharmacokinetics, efficacy and safety of CT-P10 and innovator rituximab in patients with rheumatoid arthritis.
Ann Rheum Dis
; 76(3): 566-570, 2017 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-27624791
2.
Partial remission in ankylosing spondylitis and non-radiographic axial spondyloarthritis in treatment with infliximab plus naproxen or naproxen alone: associations between partial remission and baseline disease characteristics.
Rheumatology (Oxford)
; 55(11): 1946-1953, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27411482
3.
Efficacy, Safety and Pharmacokinetics of Up to Two Courses of the Rituximab Biosimilar CT-P10 Versus Innovator Rituximab in Patients with Rheumatoid Arthritis: Results up to Week 72 of a Phase I Randomized Controlled Trial.
BioDrugs
; 31(4): 357-367, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28612179
4.
Efficacy and Safety of Switching from Innovator Rituximab to Biosimilar CT-P10 Compared with Continued Treatment with CT-P10: Results of a 56-Week Open-Label Study in Patients with Rheumatoid Arthritis.
BioDrugs
; 31(4): 369-377, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28600696